HYULIM A-TECH

Hyulim A-Tech is a South Korean company that operates in the automotive components and biotechnology sectors. Originally established in 1993 as an automotive parts manufacturer, the company expanded into the life sciences industry through the acquisition of immunotherapy assets, including the monoclonal antibody oregovomab and the MUC1-targeting antibody mAb-AR20.5. While its primary revenue is generated from supplying interior and exterior materials to major automakers like Hyundai and Kia, Hyulim A-Tech maintains a strategic presence in biotech through its pipeline of cancer treatments. The company is a member of the Hyulim Group and is publicly traded on the KOSDAQ exchange. Its biotechnology efforts focus on developing targeted immunotherapies for solid tumors, particularly in pancreatic and ovarian cancers.